What is NVG-291?

NVG-291 is an investigational peptide being developed by NervGen for spinal cord injury. It is designed to influence PTPsigma, a receptor involved in signals that can limit nerve growth after injury. The aim is to improve useful connections and function. Whether it can do that reliably in people is the question the clinical trials must answer.

There is now human evidence to discuss, as well as animal research. The sponsor has reported encouraging findings from a small controlled trial, alongside outcomes that did not clearly improve. A larger Phase 3 study is recruiting. That is meaningful progress, but it is not yet a confirmed treatment benefit or marketing approval. Current Phase 3 record.

How did the idea reach human trials?

Much of the earlier work used intracellular sigma peptide, or ISP, a research peptide related to the clinical candidate. These materials should not be treated as interchangeable. In a rat spinal cord injury study, ISP improved movement and bladder function. Later work in cultured rat nerve cells linked its effects to an enzyme that breaks down growth-inhibiting material. Those experiments help explain the proposed mechanism; they do not show that NVG-291 repairs a human spinal cord. Original rat study; Cell-mechanism study.

Other ISP experiments reported improved myelin repair and visual pathway function in mice with experimentally induced demyelination, and better outcomes in a mouse model of early-life brain injury. These are specific animal models. They do not establish treatment benefit for people with multiple sclerosis, stroke or childhood brain injury. Demyelination study; Early-life brain-injury study.

What did the first human studies test?

The Phase 1 study tested escalating doses in healthy adults. Its registry records 74 participants and completion in 2023. Its main purpose was safety and tolerability, not recovery from spinal cord injury. No summary results are posted in that registry record. Phase 1 record.

CONNECT then studied people with cervical spinal cord injuries, meaning injuries in the neck region. The published sponsor results concern 20 participants with chronic motor-incomplete injuries, one to ten years after injury. Motor-incomplete means that some movement remains below the injury. Ten received NVG-291 and ten placebo. Sponsor report, June 2, 2025.

What improved in CONNECT, and what did not?

According to NervGen, the treated group improved on the electrical-response measure for a hand muscle (P = 0.0155). The corresponding leg-muscle measure did not reach statistical significance. These were the two prespecified main measures; the study allowed success on either with a stricter significance threshold.

The hand-task score favored NVG-291, but the reported comparison was not statistically significant (P = 0.1416). The initial analysis also found no clear effects on pinch force, walking speed, or upper- and lower-limb motor scores. An electrical signal is not the same outcome as being able to perform a daily task. Initial results and their limits.

Later sponsor reports described continued hand-function improvements at week 16 and participant-reported gains in daily independence, bladder control and muscle stiffness. In the follow-up interviews, 6 of 8 treated participants reported being much or very much improved overall, compared with 3 of 9 receiving placebo. These experiences matter, but the small numbers and incomplete interview responses limit how broadly they can be applied. Sponsor follow-up report, November 24, 2025.

In May 2026, NervGen also reported a positive blinded analysis of walking mechanics using data from the same chronic cohort. That analysis examined a combination of movement measures. It is additional analysis of the earlier trial, not another independent clinical trial, and it does not erase the initial inconclusive walking-speed result. Sponsor gait-analysis report.

These clinical findings are reported here as sponsor reports. We did not locate a full peer-reviewed CONNECT results paper in the searches used for this review. ClinicalTrials.gov lists CONNECT as completed, with 24 participants overall and no posted summary results. NervGen announced the closure of enrollment in the separate subacute cohort in April 2026. The chronic-cohort findings should not be presented as results for both groups. CONNECT record; Sponsor subacute-cohort update.

What is the Phase 3 RESTORE study asking?

As checked November 9, 2026, RESTORE is recruiting, with an estimated target of 150 adults with chronic cervical motor-incomplete spinal cord injury. Its main outcome is the change in a hand-task assessment after 12 weeks. This is a direct test of functional performance, supported by measures of independence, symptoms and safety. The target sample is a plan, not a count of people already treated. RESTORE design and current status.

NervGen announced the first participant was dosed on October 12, 2026. There are no RESTORE results yet. The study will need to determine whether the earlier signals translate into a consistent, meaningful benefit with an acceptable safety profile. Sponsor trial-start announcement.

What remains uncertain about safety?

The initial CONNECT report described mild or moderate injection-site reactions as the most common adverse event, with no serious adverse events or treatment discontinuations in the treated group. That is reassuring within a group of ten people, but it cannot establish uncommon or longer-term risks. Reported safety findings.

The Phase 1 and CONNECT registry records do not provide posted adverse-event tables. Until larger, fully reported studies are available, safety claims should stay tied to the actual people, treatment duration and product studied. A vial offered by another supplier cannot inherit the clinical trial product's identity or safety evidence.

Can someone access NVG-291?

Research participation is one route for people who meet the trial criteria. The study team determines eligibility. The current RESTORE criteria focus on a defined group of chronic, motor-incomplete cervical injuries, so they do not apply to every person with spinal cord injury. Official trial information.

There is also a restricted expanded-access policy. NervGen may consider a treating physician's request for someone who completed CONNECT, received active NVG-291, had significant clinical benefit and has no other available treatment options. Supply, medical suitability and regulatory requirements still apply. This is case-by-case access for selected former participants, not general availability or an approval. Current expanded-access policy.

What should someone ask the study team?

  • Does my injury level, timing and remaining function match the trial?
  • Which changes would matter most in my daily life, and how will they be measured?
  • What are the treatment, rehabilitation and follow-up commitments?
  • What risks are known, what remains uncertain, and what happens after participation ends?

The useful next step for the evidence is a larger, well-reported comparison. NVG-291 now has early human signals and an active Phase 3 program. Keeping the encouraging and inconclusive findings together gives a more accurate picture of where it stands.

Questions people ask

Has NVG-291 helped people in a clinical trial?

NervGen has reported encouraging electrical-response and functional findings from a small controlled trial. Some important comparisons were not statistically significant. A larger Phase 3 trial is underway to test benefit and safety more reliably.

Are NVG-291 and ISP the same research material?

They are related, but the clinical candidate and the earlier experimental peptides should not be treated as interchangeable. Animal or cell findings with ISP do not establish clinical benefit from NVG-291.

Is NVG-291 only accessible within a trial?

Trial participation is one route. NervGen also has a restricted expanded-access policy for selected former CONNECT participants who received active treatment and benefited. Requests must come from the treating physician and are considered individually.

Does RESTORE show that NVG-291 works?

No results are available yet. RESTORE is a recruiting Phase 3 study designed to test hand function and other outcomes in a defined spinal cord injury population. Starting a trial is not proof of effectiveness or drug approval.

The evidence

Original preclinical studies, current trial records and clearly identified sponsor reports. Related research is searchable on our Science page.

PRECLINICALLang et al. PTPsigma modulation after spinal cord injury in rats (2015). PMID:25470046
PRECLINICALTran et al. ISP, cathepsin B and axon outgrowth in cultured rat neurons (2018). PMID:29760175
PRECLINICALNiknam et al. ISP and remyelination in mice with demyelinated optic chiasm (2019). PMID:31276750
PRECLINICALPTPsigma inhibition in a mouse model of preterm brain injury (2023). PMID:37806512
TRIAL REGISTRYNVG-291 Phase 1 healthy-adult study; completed, 74 participants, no results posted. NCT05308953
TRIAL REGISTRYCONNECT; completed, 24 participants overall, no results posted. NCT05965700
SPONSOR REPORTNervGen. Initial chronic-cohort CONNECT results, June 2, 2025. Read source
SPONSOR REPORTNervGen. CONNECT follow-up and participant interviews, November 24, 2025. Read source
SPONSOR REPORTNervGen. Additional CONNECT gait analysis, May 26, 2026. Read source
SPONSOR UPDATENervGen. RESTORE design and closure of subacute-cohort enrollment, April 7, 2026. Read source
TRIAL REGISTRYRESTORE Phase 3; recruiting, estimated target 150, no results posted. NCT07799532
SPONSOR UPDATENervGen. First RESTORE participant dosed, October 12, 2026. Read source
ACCESS POLICYNervGen. Expanded Access Policy for NVG-291. Read source

Sources checked November 9, 2026. ClinicalTrials.gov records were checked directly. The preclinical findings were checked against the original study abstracts; their full methods and datasets were not independently assessed. CONNECT findings above come from sponsor reports, not posted registry results or a full peer-reviewed results paper. No article-specific medical review is claimed.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. NVG-291 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.